Neuroendocrine Tumours could be described as an impassable obstacle, more complicated the more you research. That's where Michael and Josh come in, and this week, explore Grade 3 metastatic neuroendocrine tumours. Michael provides a brilliant overview of this well-differentiated cohort and the lack of efficacy platinum chemotherapies have, while Josh discusses CAPTEM (temozolomide and capecitabine) through a systematic review. Interestingly many of the current data is retrospectively collected, highlighting how challenging it is to collect enough patients to pursue meaningful research.
Note- there is a quote from Lance Armstrong, who was stripped of his titles due to illegal doping (which we do not endorse); he did start the Livestrong Foundation to support those affected by cancer.
Links to studies discussed in this episode (subscription may be required):
1. Review - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158108/
2. Cape/tem - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790144/
3. Platinum-based chemo: https://erc.bioscientifica.com/view/journals/erc/20/5/649.xml
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}